180 Life Sciences (ATNF) Competitors $0.90 +0.02 (+2.43%) Closing price 04/17/2025 03:55 PM EasternExtended Trading$0.86 -0.04 (-4.62%) As of 04/17/2025 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATNF vs. ANVS, ELEV, EQ, CMMB, LSTA, BFRG, LPCN, EDSA, UBX, and BCTXShould you be buying 180 Life Sciences stock or one of its competitors? The main competitors of 180 Life Sciences include Annovis Bio (ANVS), Elevation Oncology (ELEV), Equillium (EQ), Chemomab Therapeutics (CMMB), Lisata Therapeutics (LSTA), Bullfrog AI (BFRG), Lipocine (LPCN), Edesa Biotech (EDSA), Unity Biotechnology (UBX), and BriaCell Therapeutics (BCTX). These companies are all part of the "pharmaceutical products" industry. 180 Life Sciences vs. Annovis Bio Elevation Oncology Equillium Chemomab Therapeutics Lisata Therapeutics Bullfrog AI Lipocine Edesa Biotech Unity Biotechnology BriaCell Therapeutics 180 Life Sciences (NASDAQ:ATNF) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends. Do insiders and institutionals hold more shares of ATNF or ANVS? 4.1% of 180 Life Sciences shares are owned by institutional investors. Comparatively, 15.8% of Annovis Bio shares are owned by institutional investors. 0.2% of 180 Life Sciences shares are owned by insiders. Comparatively, 32.3% of Annovis Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts rate ATNF or ANVS? Annovis Bio has a consensus price target of $37.00, suggesting a potential upside of 2,883.87%. Given Annovis Bio's stronger consensus rating and higher probable upside, analysts clearly believe Annovis Bio is more favorable than 180 Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 180 Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Annovis Bio 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, ATNF or ANVS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio180 Life SciencesN/AN/A-$19.93MN/AN/AAnnovis BioN/AN/A-$56.20M-$2.56-0.48 Which has more volatility & risk, ATNF or ANVS? 180 Life Sciences has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Does the MarketBeat Community prefer ATNF or ANVS? Annovis Bio received 28 more outperform votes than 180 Life Sciences when rated by MarketBeat users. Likewise, 93.75% of users gave Annovis Bio an outperform vote while only 20.00% of users gave 180 Life Sciences an outperform vote. CompanyUnderperformOutperform180 Life SciencesOutperform Votes220.00% Underperform Votes880.00% Annovis BioOutperform Votes3093.75% Underperform Votes26.25% Is ATNF or ANVS more profitable? Annovis Bio's return on equity of 0.00% beat 180 Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets 180 Life SciencesN/A -558.93% -54.10% Annovis Bio N/A N/A -311.00% Does the media refer more to ATNF or ANVS? In the previous week, 180 Life Sciences' average media sentiment score of 0.00 equaled Annovis Bio'saverage media sentiment score. Company Overall Sentiment 180 Life Sciences Neutral Annovis Bio Neutral SummaryAnnovis Bio beats 180 Life Sciences on 10 of the 12 factors compared between the two stocks. Get 180 Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNF vs. The Competition Export to ExcelMetric180 Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.66M$6.46B$5.32B$7.35BDividend YieldN/A3.21%5.47%4.31%P/E RatioN/A6.9521.9417.82Price / SalesN/A231.01380.9497.72Price / CashN/A65.6738.3134.64Price / Book-3.745.936.453.98Net Income-$19.93M$143.22M$3.22B$247.81M7 Day Performance5.76%4.28%5.85%3.19%1 Month Performance-14.43%-13.11%-9.58%-7.70%1 Year Performance-50.63%-8.51%11.85%1.49% 180 Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNF180 Life SciencesN/A$0.90+2.4%N/A-50.6%$4.66MN/A0.007ANVSAnnovis Bio1.474 of 5 stars$1.24-5.0%$37.00+2,896.0%-87.7%$17.58MN/A-0.283Gap UpELEVElevation Oncology3.0574 of 5 stars$0.29+4.9%$3.39+1,052.4%-89.8%$17.40MN/A-0.3640News CoverageGap UpEQEquillium3.0523 of 5 stars$0.49+1.5%$3.00+516.9%-70.7%$17.32M$41.10M-3.4740Short Interest ↓Positive NewsGap UpCMMBChemomab Therapeutics2.8444 of 5 stars$1.18+10.7%$9.00+662.4%+64.7%$16.95MN/A-1.1820Positive NewsGap UpLSTALisata Therapeutics2.1832 of 5 stars$1.96+0.5%$15.00+665.3%-16.3%$16.90M$1M-0.7830News CoveragePositive NewsBFRGBullfrog AI0.6186 of 5 stars$1.79-14.8%N/A-38.5%$16.85M$60,000.00-2.114Short Interest ↑News CoverageHigh Trading VolumeLPCNLipocine2.6318 of 5 stars$3.12+1.6%$10.00+220.5%-43.1%$16.69M$11.20M-4.1110Analyst ForecastEDSAEdesa Biotech3.1897 of 5 stars$2.38+5.8%$21.00+782.4%-49.2%$16.64MN/A-1.2720Short Interest ↓UBXUnity Biotechnology3.7187 of 5 stars$0.97-2.0%$5.33+449.8%-35.3%$16.36M$240,000.00-0.7460Upcoming EarningsBCTXBriaCell Therapeutics1.4142 of 5 stars$4.38+0.7%$32.00+630.6%-85.8%$16.25MN/A-0.338News CoveragePositive NewsGap Up Related Companies and Tools Related Companies ANVS Competitors ELEV Competitors EQ Competitors CMMB Competitors LSTA Competitors BFRG Competitors LPCN Competitors EDSA Competitors UBX Competitors BCTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATNF) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...Brownstone Research | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 180 Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share 180 Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATNF Stock Free ATNF Stock Alerts